BACKGROUND: Little is known about the clinical significance of TS and DPD in pancreatic cancer. We aimed to evaluate TS and DPD expression levels in not only pancreatic cancer but also surrounding normal pancreatic tissues to assess the clinical implications of the expression of TS and DPD in this study. PATIENTS AND METHODS: Pancreatic cancer and normal pancreatic tissues were obtained from 18 patients with pancreatic cancer who underwent pancreatic resection to measure TS and DPD activities. The TS and DPD activities were determined by enzyme-linked immunosorbent assay using non-fixed fresh-frozen specimens. RESULTS: Pancreatic cancer tissues had significantly higher DPD and TS enzyme activities than surrounding normal tissue. Anaplastic ductal carcinoma had higher DPD and TS activities than the other histological types. Patients with high DPD in this study demonstrated poorer prognosis than those with low DPD. On the other hand, there was no statistically significant difference in survival between the high and the low TS groups. CONCLUSIONS: The efficacy of 5-FU may be lower in pancreatic cancer tissue than in normal tissue because DPD activity is upregulated in pancreatic cancer tissue compared to normal pancreatic tissue. It is necessary to develop an effective 5-FU delivery system and/or 5-FU combined with an inhibitor for DPD that can be used when 5-FU must be administered to patients with pancreatic cancer. High DPD activity may be a prognostic factor in patients with pancreatic cancer.
BACKGROUND: Little is known about the clinical significance of TS and DPD in pancreatic cancer. We aimed to evaluate TS and DPD expression levels in not only pancreatic cancer but also surrounding normal pancreatic tissues to assess the clinical implications of the expression of TS and DPD in this study. PATIENTS AND METHODS: Pancreatic cancer and normal pancreatic tissues were obtained from 18 patients with pancreatic cancer who underwent pancreatic resection to measure TS and DPD activities. The TS and DPD activities were determined by enzyme-linked immunosorbent assay using non-fixed fresh-frozen specimens. RESULTS:Pancreatic cancer tissues had significantly higher DPD and TS enzyme activities than surrounding normal tissue. Anaplastic ductal carcinoma had higher DPD and TS activities than the other histological types. Patients with high DPD in this study demonstrated poorer prognosis than those with low DPD. On the other hand, there was no statistically significant difference in survival between the high and the low TS groups. CONCLUSIONS: The efficacy of 5-FU may be lower in pancreatic cancer tissue than in normal tissue because DPD activity is upregulated in pancreatic cancer tissue compared to normal pancreatic tissue. It is necessary to develop an effective 5-FU delivery system and/or 5-FU combined with an inhibitor for DPD that can be used when 5-FU must be administered to patients with pancreatic cancer. High DPD activity may be a prognostic factor in patients with pancreatic cancer.
Authors: D Edler; U Kressner; P Ragnhammar; P G Johnston; I Magnusson; B Glimelius; L Påhlman; G Lindmark; H Blomgren Journal: Clin Cancer Res Date: 2000-02 Impact factor: 12.531
Authors: Ying Chuan Hu; Richard A Komorowski; Shannon Graewin; Galen Hostetter; Olli-P Kallioniemi; Henry A Pitt; Steven A Ahrendt Journal: Clin Cancer Res Date: 2003-09-15 Impact factor: 12.531
Authors: H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: D T Silverman; M Schiffman; J Everhart; A Goldstein; K D Lillemoe; G M Swanson; A G Schwartz; L M Brown; R S Greenberg; J B Schoenberg; L M Pottern; R N Hoover; J F Fraumeni Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: Hongmei Zeng; Herbert Yu; Lingeng Lu; Dhanpat Jain; Mark S Kidd; M Wasif Saif; Stephen J Chanock; Patricia Hartge; Harvey A Risch Journal: Pancreas Date: 2011-07 Impact factor: 3.327
Authors: N O Elander; K Aughton; P Ghaneh; J P Neoptolemos; D H Palmer; T F Cox; F Campbell; E Costello; C M Halloran; J R Mackey; A G Scarfe; J W Valle; A C McDonald; R Carter; N C Tebbutt; D Goldstein; J Shannon; C Dervenis; B Glimelius; M Deakin; R M Charnley; Alan Anthoney; M M Lerch; J Mayerle; A Oláh; M W Büchler; W Greenhalf Journal: Br J Cancer Date: 2018-03-08 Impact factor: 7.640
Authors: Mikael Öman; Yvonne Wettergren; Elisabeth Odin; Sofia Westermark; Peter Naredi; Oskar Hemmingsson; Helena Taflin Journal: Cancer Chemother Pharmacol Date: 2021-06-16 Impact factor: 3.333